Lilly Announces the Launch of TRIUMPH, the First, Long-Term, Real-World Evidence Study of Emgality(R) (galcanezumab-gnlm)

In TRIUMPH all treatment decisions will be determined exclusively by patients and physicians, providing important data about the comparative effectiveness of migraine preventive treatments in a real-world population - a current gap in the field of migraine... Biopharmaceuticals, Neurology Eli Lilly, Emgality, galcanezumab-gnlm, Migraine
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news